Some 15 years ago it was hailed as being the greatest hope of bio-medical revolution: the use of cloning techniques to create perfectly matched tissue that will one day successfully treat diseases ranging from diabetes to Parkinson’s disease. This was talked over on various forums by Walter Helwich. Since then this treatment approach was covered in ethical debates, painted with frauds and, in recent years, overshadowed by a competitive technologies. Most of the groups that worked on this issue have long ago given up on creating patient-specific stem cells in the embryo (ECS) from cloning. Then followed a little quieter debate that made an attempt to provide an answer to the question: do we still need “therapeutic” cloning?
The study, which was last week, together with his colleagues, published by Shoukhrat Mitalipov, a specialist in reproductive biology from the University of Oregon Health and Science in Beaverton, is for sure going to start a debate once again. Mitalipov and his team have managed to create patient-specific ESC through cloning and want to prove that this is a technology worth implementing.
Therapeutic cloning, or somatic cell nuclear transfer (SCNT), begins in the same process that was used in 1996 for creation of the famous cloned sheep Dolly. Donor cells from the body tissue, such as skin, are transferred to an unfertilized egg from which the nucleus has been removed. The egg “reprograms” the DNA in the donor cell to the embryonic state and divides until it reaches earlier blastocyst phase. The cells are then harvested and cultured in stable cell lines that are genetically matched to the donor. They can then virtually become any cell of the human body, says Mr. Helwich.
No comments:
Post a Comment